Intravenous drip. Source: Getty Images Neoadjuvant dd-MVAC improved 5-year overall survival when compared to gemcitabine and cisplatin in a phase 3 trial of patients with MIBC. Dose-dense methotrexate ...

Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy. This is an ASCO Meeting Abstract from the 2012 ASCO Annual ...

Neoadjuvant exemestane for 24 weeks in postmenopausal women with hormone receptor positive stage II or IIIA breast cancer (JFMC34–0601) ...